Accessibility Menu
GeneDx Stock Quote

GeneDx (NASDAQ: WGS)

$130.35
(-4.5%)
-6.09
Price as of November 13, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$130.35
Daily Change
(-4.5%) $6.09
Day's Range
$127.59 - $137.84
Previous Close
$130.35
Open
$134.99
Beta
1.87
Volume
607,581
Average Volume
576,002
Market Cap
3.9B
Market Cap / Employee
$136.44M
52wk Range
$55.17 - $147.71
Revenue
-
Gross Margin
0.65%
Dividend Yield
N/A
EPS
$0.06
CAPs Rating
-
Industry
Healthcare Providers and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

GeneDx Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
WGS+77.38%-59.58%-16.57%-58%
S&P+14.49%+91.09%+13.83%+99%

GeneDx Company Info

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

News & Analysis

Financial Health

General

Q3 2025YOY Change
Revenue$116.74M51.9%
Gross Profit$79.43M83.0%
Gross Margin68.04%11.6%
Market Cap$3.09B170.7%
Market Cap / Employee$3.09M0.0%
Employees1K0.0%
Net Income-$7.64M8.1%
EBITDA$3.35M383.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$95.97M65.8%
Accounts Receivable$60.94M59.4%
Inventory10.6-1.9%

Liabilities

Q3 2025YOY Change
Long Term Debt$108.73M-3.3%
Short Term Debt$5.66M15.4%

Ratios

Q3 2025YOY Change
Return On Assets0.46%20.7%
Return On Invested Capital-168.58%38.5%

Cash Flow

Q3 2025YOY Change
Free Cash Flow$9.60M290.3%
Operating Free Cash Flow$15.77M458.7%

Valuation

MetricQ2 2025Q3 2025YoY Change
Price to Earnings4936.361786.73-
Price to Book10.3110.1210.2311.1689.51%
Price to Sales7.057.557.587.7179.27%
Price to Tangible Book Value49.7428.6425.7435.34-12.08%
Price to Free Cash Flow TTM3309.14200.61-
Enterprise Value to EBITDA145.301453.90179.17913.75-193.85%
Free Cash Flow Yield0.0%0.5%-
Return on Equity-22.1%-16.6%0.6%0.8%-102.30%
Total Debt$117.38M$116.05M$115.61M$114.39M-2.49%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.